TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 107 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q3 2015. The put-call ratio across all filers is 1.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $48,000 | -67.8% | 100,613 | -9.7% | 0.00% | -66.7% |
| Q1 2019 | $149,000 | +39.3% | 111,388 | +18.0% | 0.01% | +28.6% |
| Q4 2018 | $107,000 | -60.8% | 94,382 | -4.7% | 0.01% | -41.7% |
| Q3 2018 | $273,000 | -56.1% | 99,059 | -43.2% | 0.01% | -52.0% |
| Q2 2018 | $622,000 | -22.9% | 174,335 | -33.7% | 0.02% | -21.9% |
| Q1 2018 | $807,000 | +540.5% | 262,896 | +1324.4% | 0.03% | +433.3% |
| Q3 2017 | $126,000 | -86.3% | 18,457 | -85.7% | 0.01% | -87.8% |
| Q2 2017 | $922,000 | +147.2% | 129,425 | +218.1% | 0.05% | +188.2% |
| Q1 2017 | $373,000 | +258.7% | 40,685 | +57.1% | 0.02% | +183.3% |
| Q4 2016 | $104,000 | -97.1% | 25,900 | -92.7% | 0.01% | -96.4% |
| Q4 2015 | $3,545,000 | +133.4% | 353,527 | +73.5% | 0.17% | +200.0% |
| Q3 2015 | $1,519,000 | +1752.4% | 203,708 | +1631.5% | 0.06% | +1766.7% |
| Q2 2013 | $82,000 | – | 11,765 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |